Summit logo

Summit

Stock
Stock
ISIN: US86627T1088
Ticker: SMMT
US86627T1088
SMMT

Price

Price

CHART BY

Frequently asked questions

What is Summit's market capitalization?

The market capitalization of Summit is $12.78B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Summit?

Summit's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.308. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Summit's stock?

Currently, 10 analysts cover Summit's stock, with a consensus target price of $35.44. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Summit?

Summit's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$211.20M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Summit?

Summit has a free cash flow of -$142.66M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Summit have, and what sector and industry does it belong to?

Summit employs approximately 159 people. It operates in the Health Care sector, specifically within the Biotechnology industry.

What is the free float of Summit's shares?

The free float of Summit is 115.12M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$12.78B
EPS (TTM) 
-$0.308
Free Float 
115.12M
EBITDA (TTM) 
-$211.20M
Free Cashflow (TTM) 
-$142.66M

Pricing

52W span
$2.105$33.89

Analyst Ratings

The price target is $35.44 and the stock is covered by 10 analysts.

Buy

10

Hold

0

Sell

0

Information

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Employees
159
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
US86627T1088
Primary Ticker
SMMT
Fundamentals & EOD data from FactSet
Join the conversation